Multiple sclerosis (MS) is a chronic, frequently progressive, inflammatory CNS disease characterized pathologically by primary demyelination, usually without initial axonal injury. The etiology and pathogenesis of MS are unknown. Several immunological features of MS, and its moderate association with certain major histocompatibility complex alleles, have prompt-ed the speculation that MS is an immune-mediated disease (Hafler and Weiner, 1989; Compston, 199 1; Olsson, 1992) . An autoimmune hypothesis is supported by the experimental autoimmune (allergic) encephalomyelitis (EAE) model, where injection of certain myelin components into genetically susceptible animals leads to T cell-mediated CNS demyelination (Kabat et al., 1947; Lublin, 1985) . However, specific autoantigens and pathogenic myelin-reactive T cells have not been definitively identified in the CNS of MS patients, nor is MS associated with other autoimmune diseases. An alternative hypothesis, based upon epidemiological data (Martyn, 1991) is that an environmental factor, perhaps an unidentified virus, precipitates an inflammatory response in the CNS, which leads to either direct or indirect ("bystander") myelin destruction, potentially with an induced autoimmune component (Lampert, 1978; Rodriguez, 1988) . This hypothesis is supported by evidence that several naturally occurring viral infections, in both humans (Rice, 1992) and animals (Dal Canto and Rabinowitz, 1982) , can cause demyelination. One commonly utilized experimental viral model is induced by Theiler's murine encephalomyelitis virus (TMEV) (Dal Canto and Lipton, 1977; Rodriguez et al., 1987b) . Intracerebral inoculation of genetically susceptible mice with TMEV, a naturally pathogenic enteric picomavirus, produces a chronic, progressive, immune-mediated CNS demyelinating disease, in many aspects indistinguishable from the chronic progressive form of MS. Although some reports have suggested an association of MS with several pathogenic human viruses, no virus to date has been definitively linked with MS (Rice, 1992) . The apparently complex etiopathogenesis of MS, potentially involving both environmental and autoimmune factors, may account for the current lack of a precise animal model. The limited efficacy of current therapies for MS (Goodkin et al., 1992 ) due primarily to its unknown etiopathogenesis, has stimulated interest in novel therapies to ameliorate this disease (Martin et al., 1992; Steinman, 1992; Weiner et al., 1993) . Contrary to the classical view of the humoral immune system playing a pathogenic role in MS, several experimental studies suggest that antibodies (Ab) might play a preventative or reparative role in CNS demyelinating diseases. Injection of CNS components into either guinea pigs with EAE (Traugott et al., 1982) , or TMEV-infected mice (Lang et al., 1984) results in improved clinical disease and enhanced CNS remyelination. Although this effect was originally attributed to direct T cell immunosuppression (Traugott et al., 1982) the hypothesis that injection of myelin components would generate a therapeutic humoral immune response was directly tested in the TMEV model. Immune transfer experiments showed that promotion of remyelination in the TMEV model is mediated by a serum factor (Rodriguez et al., 1987a) , which was identified as immunoglobulin (Ig) (Rodriguez and Lennon, 1990 ). Here we report that two monoclonal Abs (mAbs), generated from uninfected mice injected with spinal cord homogenate (SCH) and screened for their autoantigen-binding capability, also promoted CNS remyelination in SJL/J mice chronically infected with TMEV. This model provides the opportunity to investigate the potential beneficial, rather than pathogenic, effect of autoantibodies during the physiological response to tissue injury in the CNS. In addition, elucidation of the mechanism(s) of Ab-mediated CNS remyelination may suggest a rational approach to augment repair in CNS demyelinating diseases.
Materials and Methods
Virus. We used the Daniel's strain (DA) of TMEV for all experiments. The tissue culture origin and production of this virus have been previously described (Rodriguez et al., 1983) . Animals. SJYJ and BALB/c mice were purchased from the Jackson MonoclonalAbproduction, screening, and&$cation. Spleens of two SJL/J mice that had been injected twice with SCH in incomplete Freund's adjuvant were used as the source of B cells for fusion and hybridoma Laboratory (Bar Harbor, ME); 4-6-week-old SJL/J mice were inoculated production. The serum Igs from these mice had been previously shown to promote remyelination in chronically infected mice (Rodriguez and intracerebrally with 2 x I O5 plaque-forming units (PFU) of TMEV in Lennon, 1990) . Splenocytes were fused with NS-1 myeloma cells using a 10 ~1 volume. MAb treatment was begun 4-6 months after infection, polyethyiene glycol, and viable cell fusions were selected with hypoxanthine-aminopterine-thymidine (HAT) media and cloned by limiting at which time the mice showed clinical signs of chronic demyelination, dilution as described (Katzmann et al., 198 1 NaCI, 50 mM phosphate, pH 7.4) containing 1% bovine serum albumin (BSA) for 1 hr, incubated with mAbs supematants for 2 hr, and washed extensively with PBS plus 0.05% Tween 20. Bound Ab was detected with alkaline phosphatase-conjugatedgoat anti-mouse Ig (Sigma Chemical Co., St Louis, MO) using p-nitrophenyl phosphate as the chromogenic substrate. The hybridomas chosen for treatment experiments were injected into pristane-treated BALB/c mice for ascites production. IgM mAbs were purified either by ammonium sulfate precipitation and gel filtration on a Sephacryl S-400 HR (Sigma) column for the initial transfer experiments, or by affinity chromatography using goat antimouse IgM (r-chain specific; Jackson Immunoresearch, West Grove, PA) coupled to Reacti-Gel 6X matrix (Pierce, Rockford. IL) for later transfer experiments.
Light and electron micrograph preparation and assessment of remyelination. Preparation of light and electron microscopy sections and morphological assessment of remyelination were done as previously described (Rodriguez and Lennon, 1990) . Briefly, treated mice were anesthetized with pentobarbital(O.2 mg, i.p.), exsanguinated by cardiac puncture, and killed by intracardiac perfusion with Trump's fixative (100 mM phosphate buffer, pH 7.2, with 4% formaldehyde and 1.5% glutaraldehyde). The entire spinal cord was removed carefully from the spinal canal, and sectioned into 1 mm transverse blocks. Every third block was postfixed in 1% osmium tetroxide and embedded in Araldite (Polysciences, Warrington, PA). One-micrometer sections from each block were cut and stained with p-phenylenediamine. On each section, remyelination was quantitated using a Zeiss interactive digital analysis system (ZIDAS) and camera lucida attached to a Zeiss photomicroscope (Carl Zeiss Inc., Thomwood, NV). Abnormally thin myelin sheaths relative to axonal diameter was used as the criterion for CNS remyelination (Ludwin, 1985 (Ludwin, , 1988 Fig. 1A.D) . Ten spinal cord sections from each mouse were examined; this corresponded to 8-9 mm2 of white matter examined per mouse. To avoid bias, slides were coded and quantitation was done without knowledge of the treatment groups.
counted the number of myelinated axons in lesions from plastic-embedded spinal cord sections using the analysis system described above ated was the presence of substantial demyelination with minimal repair, whereas remyelinated lesions were chosen based upon the presence of Image Analysis System (Kontron, Munich, Germany). We measured almost complete remyelination throughout the lesion.
the axonal cross-sectional area with and without the myelin sheath, and used equivalent circle calculations to determine the axonal diameter and myelin sheath thickness. For myelinated axon quantitation, we
Treatment protocol and clinical disease assessment. Chronically infected mice were given either intraperitoneal or intravenous iniections of mAb twice weekly for 4-5 weeks. At each treatment injection, mice were assessed clinically by three criteria: appearance, activity, and paralysis. A score for each criterion was given ranging from 0 (no disease) to 3 (severe disease). For appearance, 1 indicated minimal change in coat, 2 indicated a moderate change (scruffy appearance), and 3 indicated a severe change (incontinence and stained coat). For activitv. 1 indicated decreased-spontaneous movements (minimal ataxia), 2-mdicated moderate slowing (minimal spontaneous movements), and 3 indicated severe slowing (no spontaneous movement). For paralysis, 0.5 indicated a spastic extremity, 1 indicated a paralyzed extremity, 1.5 indicated two or more spastic extremities, 2 indicated two paralyzed extremities (unable to walk), 2.5 indicated no righting response, and 3 indicated three or four paralyzed extremities (moribund). The total score for each mouse was the cumulative total from each criterion (maximum of 9). As the clinical score was an ordinal and not a cardinal scale, we used the change in clinical score to assess clinical disease. The clinical assessment data were not disclosed until after the morphological assessment of remyelination was completed. TME V Western blot. Confluent L2 fibroblast cells were infected with TMEV as described (Rodriguez et al., 1983) . After 48 hr, cells were solubilized in sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) sample buffer (62.5 mM Tris, pH 6.8, 5% glycerol, 2% SDS, 14.4 mM 2-mercaptoethanol, 0.02% bromophenol blue), and proteins were separated by SDS-PAGE on 15% acrylamide gels and transferred to nitrocellulose by electroblotting. Mock-infected L2 cell lysates were used as a control antigen source to detect Ab reactivity with nonviral proteins. All electrophoresis and electroblotting were done with the Mini-PROTEAN II apparatus (Bio-Rad, Hercules, CA). Nitrocellulose was air dried for 24 hr, rehydrated in water, and blocked with Tris-buffered saline (TBS; 100 mM NaCI, 50 mM Tris, pH 7.4) containing 3% nonfat milk and 0.03% Tween 20 for 1 hr at room temperature. Nitrocellulose was incubated with control or SCH mAbs (5 &ml), polyclonal rabbit anti-TMEV (1:2000; Rodriguez et al., 1983) , or serum from chronically infected mice (1:200), diluted in blocking buffer for 2 hr and washed extensively with TBS containing 0.03% Tween 20. Bound Ab was detected with alkaline phosphatase-labeled goat anti-mouse IgG + IgM or goat anti-rabbit IgG (Jackson Immunoresearch, West Grove, PA) using 5-bromo-4-chloro-3-indolyl phosphate and nitro blue tetrazolium (BCIP/NBT) in 100 mM NaCI, 100 mM Tris, 5 mM MgCl,, pH 9.5: as the substrate.
In vitro TME V neutralization assay. Viral plaque assays were done as previously described (Patick et al., 199 1) . To assess neutralization, aliauots of TMEV (200 PFU/ml) were incubated with various concentrations of Ab for I hr at room temperature prior to plating onto confluent L2 cells. As a positive control, we used serum from susceptible mice chronically infected with TMEV. Under the assay conditions described above, a serum dilution of 1:34,000 gave 50% neutralization, which corresponded to an estimated 20 &ml of TMEV-specific Abs, assuming a total serum Ig concentration of 15 mg/ml, and a TMEVspecific fraction of 5%.
Zmmunostaining. Rat 5.5B8 glial cells were grown on poly-m-lysinecoated chamber slides in Dulbecco's modified Eagle's medium (DMEM) supplemented with 1.5 gm/liter D-glucose, 30 nM SeO,, 15 nM triiodothyronine, 10 @ml biotin, 100 PM ZnCI,, 50 r&ml gentamicin, and 10% fetal bovine serum. All staining steps were done at room temper- ature. For surface staining, slides were briefly rinsed with PBS, and cells were lightly fixed with 1% formaldehyde in PBS for 10 min to prevent cell detachment during subsequent staining steps. For cytoplasmic staining, slides were rinsed twice in PBS and either air dried for 1 hr or incubated with 0.1% Triton X-100 in PBS for 10 min. Cells were blocked in 2% BSA for 30 min, washed, incubated with control IgM or mAb SCH94.03 (10 &ml in 1% BSA) for 1 hr, and washed extensively with PBS. After fixation with 4% paraformaldehyde for 15 min, slides were incubated with fluorescein-labeled goat anti-mouse IgM (Jackson Immunoresearch) for 1 hr, washed with PBS, coverslipped with 10% MOWIOL (Hoechst) in 100 mM Tris, 25% glycerol, pH 8.5, with 25 &ml 1,4-diazobicyclo-[2.2.2]-octane (DABCO) to prevent fading, and allowed to set overnight in the dark. For frozen tissue sections, fresh neonatal rat, adult mouse, or autopsied human cortical brain tissue was quick frozen in isopentane chilled in liquid nitrogen prior to liquid nitrogen storage. Frozen sections (10 pm) were transferred onto gelatinized glass microscope slides, air dried for 4-8 hr, and stored at -70°C. Prior to immunostaining, slides were placed at room temperature over-night. The immunoperoxidase staining protocol was similar that described above, using the ABC immunoperoxidase reagent (Vector Laboratories, Burlingame, CA), developed with 1.5 mg/ml Hanker-Yates reagent (p-phenylene diamine-procatechol) in 50 mM Tris, pH 7.6, with 0.034% H,O,, counterstained with Mayer's hematoxylin, and mounted with Permount (Fischer Scientific, Pittsburgh, PA).
Data analysis. We used a modified cumulative rank sum test (O'Brien, 1984) to compare remyelination between treatment groups. This statistical test takes into account several numerically unrelated parameters oftherapeutic effectiveness, and is used routinely for clinical trial efficacy assessment. Parallel analyses using a standard unpaired Student's t test to compare individual parameters of remyelination gave equivalent results. Comparisons of disease severity and correlation significance were determined by a one-way analysis ofvariance (ANOVA). Statistical analyses were done with the either the SIGMASTAT (Jandel Scientific, San Rafael, CA) or EXCEL (Microsoft Corporation, Redmond, WA) software programs. Calculated values were considered significant when p was < 0.05.
Results

Selection of SCH mAbs to promote CNS remyelination
We constructed a panel of mAbs derived from splenocytes of uninfected SJL/J mice injected with SCH, whose serum Igs were shown previously to promote remyelination in vivo (Rodriguez and Lennon, 1990) . After the initial fusion and cloning, 2 of the 95 wells with viable Ig-secreting hybridomas contained Ab with significant binding to SCH by ELISA. Hybridoma cells from these two wells, called the 79 and 94 series, were subcloned by limiting dilution and screened again for binding to SCH by ELISA. For the 79 series hybridomas, 14 of 49 clones were positive by SCH ELISA, while for the 94 series, 17 of 32 were positive for binding to SCH. Based upon the ELISA data, we chose two 79 series hybridomas (SCH79.08 and SCH79.27), both of which also reacted with myelin basic protein (MBP) by ELISA, and three 94 series hybridomas (SCH94.03, SCH94.11, and SCH94.32), none of which reacted with MBP, for ascites production and in vivo transfer experiments. Initial treatment experiments showed that mAbs from SCH94.03 and SCH94.32, both of which were an IgM isotype, promoted significantly more CNS remyelination in mice chronically infected with TMEV than the other three hybridomas, and therefore were chosen for a more detailed examination of their potential to promote CNS repair.
CNS remyelination promoted by mAbs SCH94.03 and SCH94.32 SJWJ mice chronically infected with TMEV and treated with either mAb SCH94.03 or SCH94.32 showed significantly greater CNS remyelination than animals treated with either isotypematched control Ab or buffer only (Table 1) . Remyelination was seen with either intravenous or intraperitoneal injections (data pooled). SCH94.03-or SCH94.32-treated animals had approximately two-to threefold more remyelinated lesions, and a threeto fourfold larger total area of CNS remyelination than control animals. When a cumulative statistical comparison was made using these two parameters of therapeutic effectiveness, the CNS remyelination induced by mAbs SCH94.03 and SCH94.32 was highly significant (p < 0.005; Table 1 ). In a chronic progressive disease like TMEV infection, the extent of CNS repair is a direct function of the extent of CNS damage. Both the number and area of CNS lesions were not different between treatment groups, indicating similar disease severity (Table 1) . When CNS remyelination was expressed as the percentage of lesion area showing remyelination, approximately one-third of the cumulative demyelinated lesion area showed CNS remyelination in mice treated with either mAb SCH94.03 or SCH94.32 (Table 1 ). The extent of remyelination was comparable to that observed previously in mice treated with SCH antiserum (Rodriguez et al., 1987a) or SCH IgG (Rodriguez and Lennon, 1990 ).
Morphology of CNS remyelination CNS remyelination was readily identified morphologically both by light and electron microscopy (Fig. 1) . Figure 1A shows a remyelinated lesion from an animal treated with SCH94.03. The majority of axons in the lesion show morphologic evidence of repair, with abnormally thin myelin sheaths relative to axonal diameter (Ludwin, 1985 (Ludwin, , 1988 . For comparison, Figure la shows a demyelinated lesion, with minimal remyelination, whereas Figure 1C is an area of normal myelin, with thickly myelinated axons. Within remyelinated lesions (Fig. lA) , there were 15.3 * 1 .O (mean + SEM) myelinated axons per 100 pmZ, compared to only 1.1 f 0.2 myelinated axons per 100 pm* in demyelinated lesions (Fig. 1B) . By electron microscopy, CNS remyelination was especially evident (Fig. 1D) . Almost every axon in the field has evidence of new myelin formation, although the degree of remyelination (i.e., myelin thickness) is variable between individual axons, suggesting different stages of the repair process. The ratio of myelin thickness to axonal diameter was 0.08 + 0.01 (mean -t SEM; n = 25 axons) for remyelinated axons compared to 0.21 + 0.01 (n = 34 axons) for normally myelinated axons.
Correlation between clinical disease and morphological remyelination We assessed whether morphological remyelination correlated with clinical signs of disease improvement. At each treatment injection, mice were assessed clinically as described in Materials and Methods. We correlated the change in clinical score with the percentage of lesion area showing remyelination t'l?g. 2). A positive change in clinical score indicates worsening of disease. Using data from all treatment groups, the change in clinical score showed a moderate but significant negative correlation (R = -0.40; p < 0.04) with the percentage of lesion area showing remyelination. Although few animals actually improved clinically (A clinical score < 0), animals with an increase in disease severity (A clinical score > 0) tended to have less morphological remyelination, while animals that remained stable clinically (A clinical score = 0) showed the most remyelination. A similar negative correlation was obtained when we used the other quantitative measures of remyelination, the number of remyelinated lesions and the area of remyelination, as shown in Table 1 . We conclude that remyelinatian quantitated by morphotogy is associated with slowing of clinical disease progression.
Titration of mAb SCH94.03 dose and CNS remyelination For the initial treatment experiments, we empirically chose a total mAb dose of 25 mg/kg for intravenous injections and 250 mg/kg for intraperitoneal injections. To assess the dose-response characteristics, and to determine the minimal amount of mAb needed to promote remyelination, we treated chronically infected mice with various intraperitoneal doses of SCH94.03. Both the number of remyelinated lesions (data not shown) and the total area of remyelination (Fig. 3) increased significantly with larger doses of SCH94.03. The positive correlation between the dose of mAb SCH94.03 and CNS remyelination was especially striking when the severity of CNS disease was taken into account. When CNS repair was expressed as the Change in Clinical Score percentage of lesion area showing remyelination, mice treated with a total dose of 1000, 100, or 10 rg of SCH94.03 had six-, five-, and fourfold more remyelination than control animals, respectively (Fig. 3) . Of interest, mice given as little as 10 pg of SCH94.03 (0.5 mg/kg, i.p.) showed evidence of enhanced CNS remyelination. These data indicated that mAb SCH94.03 and CNS remyelination had a positive dose-response relationship, and that very small quantities of mAb were needed to promote myelin repair.
rabbits injected with purified TMEV (Rodriguez et al., 1983) . In addition, we observed no significant inhibition of TMEV infectivity in vitro with up to 5 &ml of either SCH94.03 or SCH94.32, under assay conditions where 50% neutralization was observed with a 1:34,000 dilution of serum from chronically infected animals. These results indicated that the therapeutic effect of SCH94.03 and SCH94.32 was not due to direct inhibition of the virus. This is consistent with the observation that chronically infected animals that show little spontaneous remyelination maintain high endogenous neutralizing Ab titers (Patick et al., 199 1) .
Antigen specificity of SCH94.03 and SCH94.32
Although mAbs SCH94.03 and SCH94.32 were generated from To characterize initially the autoantigens recognized by mAbs splenocytes of uninfected mice, and screened against SCH from SCH94.03 and SCH94.32, we immunostained various cell lines uninfected mice, we directly assessed whether either mAb could derived from glial (rat C6, mouse G26-20, human U373MG react with TMEV capsid proteins or inhibit viral infectivity in and U87MG), neural (human neuroblastoma), fibroblast (mouse vitro. By Western blotting (Fig. 4) , SCH94.03 and SCH94.32 L and 3T3), epithelial (human SCC-9 carcinoma), and lymphodid not react with any TMEV proteins recognized by either cytic (mouse CTLL2) origin. Both mAbs stained internal antiserum from chronically infected mice or polyclonal IgG from gens of all cell lines tested, which indicated that certain antigens SJUJ mice chronically infected with TMEV were treated with a total mAb dose of 0.5 mg (i.v.) or 5.0 mg (i.p.) divided into twice weekly doses for 4-5 weeks. CNS remyelination was measured by a quantitative morphological assessment on 10 spinal cord cross sections from each mouse. The criterion for CNS remyelination was abnormally thin myelin sheaths relative to axonal diameter (Ludwin, 1985 (Ludwin, , 1988  Fig. 1D ). The data are a composite of six experiments and are presented as the mean + SEM, where n indicates the number of mice. Statistical comparisons for remyelination data were made with the cumulative values from both IgM and buffer-only controls using a modified rank sum test (O'Brien, 1984) . The number of demyelinated lesions and the area of demyelination were not significantly different between treatment groups assessed by a one-way ANOVA.
For control IgMs, we used myelomas MOPC 104E and ABPC 22 (both from Sigma), and TB5-1, an anti-mycobhcteria mAb. Table 1 . Data are the mean values of four or five animals per mAb dose, with the final cumulative dose indicated on the graph; SEM averaged 35% of the mean. There was no statistical difference assessed by one-way ANOVA in the number of demyelinated lesions or the area of demyelination between treatment groups, indicating similar extent of disease in all animals. The number of demyelinated lesions and area of lesions were 33.2 + 7.5 and 1.25 f 0.43 for the 1000 pg group, 3 1.8 +-8 and 1.11 f 0.3 1 for the 100 pg group, 23.8 + 3.4 and 0.54 f 0.14 for the 10 pg group, and 29.0 + 6.5 and 0.74 + 0.20 for the buffer only group (represented as the 0 dose point on the graph). Animals treated with 100 pg of control IgM (MOPC 104E) had remyelination scores similar to control animals treated with buffer only.
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recognized by these mAbs were not restricted to unique cell types in vitro. Based on the hypothesis that the therapeutic effect of SCH94.03 and SCH94.32 was due to a CNS-specific interaction, we further investigated the immunostaining of cultured cells by SCH94.03 and SCH94.32 using the rat glial cell line 5.5B8 (Fig. 54,B) . This immortalized glial cell line has phenotypic characteristics of both oligodendrocytes and astrocytes, with expression of MBP and 2',3'-cyclic nucleotide 3'-phosphodiesterase (CNP), and low but detectable expression of glial fibrillary acidic protein (GFAP) and the lipids or proteins recognized by the mAbs A2B5 and 04 (Bozyczko et al., 1990) . SCH94.03 and SCH94.32 recognized both a surface and cytoplasmic determinant on 5.5B8 cells. The surface staining was most prominent on small cells that lay on top of a layer of flat, morphologically differentiated cells (Fig. 5A) . Surface staining was confirmed by flow cytometry on live cells. When the cell membrane was permeabilized by dehydration or brief treatment with a nonionic detergent to expose internal antigens, the staining pattern was altered considerably (Fig. 5B) Immunohistochemical staining of frozen mouse, rat, and human tissue confirmed that SCH94.03 and SCH94.32 were not CNS-specific mAbs, but rather showed multiorgan reactivity. Both mAbs immunostained all major organs examined, including the brain, spinal cord, heart, liver, kidney, stomach, and small intestine. However, not all cells within an organ stained, suggesting in situ cytological specificity (D. Miller and M. Rodriguez, unpublished observations). Within the CNS, SCH94.03 and SCH94.32 stained predominantly blood vessels, ependymal cells, and stellate-shaped cells with the morphological features of glial cells, which were enriched in neonatal cerebellar, periventricular, and brainstem white matter (Fig. 5C) , and both neonatal and adult optic nerve. Similar glial cells positive for SCH94.03 and SCH94.32 were found in autopsied human brain tissue, especially at the gray-white matter junction (Fig. 5D) .
Promote Remyelination . . (Rodriguez and Lennon, 1990) . In sessment of CNS remyelination. this report, we expand this observation and demonstrate that
We propose two potential mechanisms by which Abs promote two mAbs, generated and screened for their autoantigen-binding remyelination. First, Abs might inhibit some pathogenic com-ponent of the disease process, such as virus activity, an immune response that directly induces demyelination, or an immune response that prevents remyelination. If the disease outcome is based upon a balance between tissue destruction and repair, inhibition of pathogenic components would allow a physiological repair response to predominate. Experimental and clinical evidence support this hypothesis. Spontaneous CNS remyelination is seen in MS patients and several experimental models of CNS demyelination (Ludwin, 1988) . We also observed spontaneous remyelination in control mice (Table 1) . This indicates that remyelination is a normal physiological response to myelin damage. In addition, treatment of mice chronically infected with TMEV with various immunosuppressive regiments promotes remyelination, but does not decrease demyelination, indicating that there is an immunological component that inhibits remyelination (Rodriguez and Lindsley, 1992) . Preliminary immunological function studies have indicated that animals treated with SCH94.03 had similar numbers of B and T (both CD4+ and CD8+ ) cells in their spleens compared to control animals, had similar in vitro splenocyte proliferative responses to mitogens and antigens, and mounted comparable Ab responses to both T cell-dependent and T cell-independent antigens (Miller and Rodriguez, unpublished observations). We are currently investigating the possibility that these mAbs induce a subtle immunomodulatory effect in chronically infected animals, similar to mechanisms proposed for the therapeutic effect of polyclonal Ig in certain human inflammatory diseases (reviewed by Dwyer, 1992) .
The second hypothesis is that certain Abs can actively stimulate CNS remyelination, perhaps via stimulation of oligodendrocyte proliferation and/or differentiation in vivo, as has been demonstrated in vitro (Diaz et al., 1978; Lehrer et al., 1979; Raine et al., 1979; Bansal et al., 1988; Benjamins and Dyer, 1990; Dyer, 1993) . MAbs SCH94.03 and SCH94.32 may directly stimulate precursor oligodendrocytes, which are known to be present at the edges of both human (Raine et al., 1981; Prineas, 1985) and experimental (Moore et al., 1984; Rodriguez and Lennon, 1990 ) CNS lesions that show active remyelination. Alternatively, SCH94.03 and SCH94.32 may work indirectly, via activation of astrocytes or other accessory cells, which could release factors important for the survival or proliferation of cells in the oligodendroglial lineage. The formation of Ab-antigen complexes in situ with tissue components released upon myelin destruction may also participate in Ab-mediated CNS remyelination. Although SCH94.03 and SCH94.32 were not CNS specific, the recognition of both surface and cytoplasmic antigens on glial cells by both mAbs (Fig. 5) supports an active mechanism hypothesis. In contrast to the immunomodulatory hypothesis, which would not necessarily require that Abs have direct access to the CNS, the hypothesis that Abs actively stimulate CNS remyelination implies the prerequisite ofdirect access to the CNS. This is contrary to the view of the selective permeability of the blood-brain barrier, especially toward large molecules such as pentameric IgM. However, during chronic inflammatory conditions such as TMEV infection or MS, peripheral leukocytes migrate into the CNS, indicating an alteration in the blood-brain barrier permeability. Therefore, large proteins such as serum Ig might also enter, via either passive diffusion through "open" endothelium, or perhaps via an unidentified active transport mechanism. We are currently assessing whether SCH94.03 and SCH94.32 can enter the CNS, and whether either mAb can directly stimulate glial cells in vitro.
Definitive identification of the antigens recognized by SCH94.03 and SCH94.32 may provide some clue as to a mechanism of Ab-mediated remyelination. Our objective in the screening and selection of these mAbs was not to select for reactivity toward a unique antigen, but rather to select broadly for reactivity toward a heterogeneous mixture enriched for CNS antigens (SCH), and subsequently screen for therapeutic biological activity. Our identification of two mAbs that promoted remyelination, but were not CNS specific, was unanticipated, but not surprising. In a previous study, 19 of 30 hybridomas made using brain tissue as the immunogen reacted with both neural and non-neural tissue (Frank0 et al., 198 1) . Nineteen of these hybridomas secreted an IgM mAb, five reacted with multiple cell lines derived from different tissues, and several had immunostaining patterns suggestive of cytoskeletal proteins, similar to our observations with SCH94.03 and SCH94.32 (Fig.  5) . Our identification of two IgM monoclonal autoantibodies with multiorgan reactivity, and recognition of both surface and cytoplasmic (presumably cytoskeletal) antigens, suggests that SCH94.03 and SCH94.32 may belong to a family of antibodies known as natural autoantibodies. Natural autoantibodies, whose physiological significance is unknown, are usually IgMs, are present in the serum of normal individuals, represent a substantial fraction of the total Ig repertoire, show polyreactivity toward multiple self and nonself antigens, including cytoskeletal elements, and are typically encoded by unmutated germline Ig genes (Avrameas and Temynck, 1993) . We are directly investigating whether SCH94.03 and SCH94.32 have similar phenotypic characteristics.
In CNS demyelinating diseases, Abs are generally considered pathogenic. The initial observation that polyclonal Igs promote CNS remyelination in an animal model of MS (Rodriguez and Lennon, 1990) and our similar results with two mAbs presented in this report, questions the traditional role of autoantibodies as pathogenic, and should stimulate interest in the potentially beneficial role of autoantibodies in normal physiology. In addition, the identification of mAbs that facilitate tissue repair represents a significant step toward elucidation of the mechanism(s) involved in Ab-mediated CNS repair.
